Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708604 · ClinicalTrials.gov registry record · Phase 1
Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00708604 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT00708604, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of islet transplantation in patients with type 1 diabetes who have had a successful kidney transplant and have been maintained for at least three months on anti-rejection medications consisting of any combination of sirolimus, tacrolimus, MMF or prednisone (5 mg/day or less). Another purpose is to determine the effectiveness of an islet transplant in inducing insulin independence and whether or not an islet transplant improves quality of life for kidney transplants patients with type 1 diabetes.
Interventions
- BIOLOGICAL Islet cell transplantation
- PROCEDURE Islet Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-10-18 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00708604
The ClinicalTrials.gov registry entry for NCT00708604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Islet cell transplantation is the first listed.
NCT00708604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00708604 about?
NCT00708604 is a clinical study titled "Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes". The purpose of this study is to determine the safety of islet transplantation in patients with type 1 diabetes who have had a successful kidney transplant and have been maintained for at least three months on anti-rejection medications consisting of any combination of sirolimus, tacrolimus, MMF or p...
What is the current status of trial NCT00708604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-10-18. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00708604?
The interventions under investigation include: Islet cell transplantation (BIOLOGICAL), Islet Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00708604?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.